Pfizer narrows post-merger R&D focus

Pfizer is whacking about 100 drug development programs out of a pipeline swollen by its merger with Wyeth.  Reuters reports that the bulk of the remaining 500 programs focus on six key areas: Oncology, pain, inflammation, Alzheimer's disease, psychoses and diabetes. Report